HDAC6 Inhibitor Platform (CNS)
Frontotemporal Dementia, Parkinson's Disease, Alzheimer's Disease
PreclinicalActive
Key Facts
Indication
Frontotemporal Dementia, Parkinson's Disease, Alzheimer's Disease
Phase
Preclinical
Status
Active
Company
About Eikonizo Therapeutics
Eikonizo Therapeutics is a private, preclinical-stage biotech focused on selective HDAC6 inhibitors. Its lead CNS candidate, EKZ-102, is in IND-enabling studies for ALS, with plans to expand to other neurodegenerative diseases. The company is also developing peripheral HDAC6 inhibitors for cardiorenal indications like ADPKD and diabetic nephropathy, leveraging a platform designed for high selectivity and CNS penetrance to minimize side effects.
View full company profile